Sarepta (SRPT) on Tuesday provided a safety update on Elevidys, noting that a young Duchenne muscular dystrophy patient passed away from liver failure following treatment with Elevidys, Morgan Stanley tells investors. The safety update from Sarepta could further improve enrollment in Regenxbio’s (RGNX) pivotal DMD study and potentially alter the conversation around the potential for an accelerated approval, the firm says. Morgan Stanley has an Overweight rating and $24 price target on Regenxbio shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Analysts remain optimistic about Elevidys after Sarepta reports patient death
- Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys
- Regenxbio price target lowered to $34 from $36 at H.C. Wainwright
- RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
- REGENXBIO Earnings Call Highlights Strategic Progress